- US FTC to scrutinize drug patents listed in FDA Orange Book🔍
- FTC Investigates Use of Orange Book to Prevent Competition🔍
- FTC Challenges More Patent Listings in the FDA's Orange Book🔍
- Warren Urges FTC To Closely Scrutinize Novo Nordisk|Catalent ...🔍
- The Antitrust Prescription🔍
- The Current Status of FTC'S Orange Book Listings Challenge🔍
- FTC Alleges Improper Orange Book Listing of Drug Delivery Device ...🔍
- FTC Votes to Scrutinize High Drug Prices🔍
Increased Scrutiny by Federal Trade Commission of Orange Book ...
US FTC to scrutinize drug patents listed in FDA Orange Book - MLex
Pharmaceutical companies were put on notice today by a senior Federal Trade Commission enforcer over improperly listed patents that could ...
FTC Investigates Use of Orange Book to Prevent Competition
Alleged Misuse of the FDA's Orange Book as an Anticompetitive Vehicle: Attorney Insights on Recent Scrutiny by the FTC based on theNovember ...
FTC Challenges More Patent Listings in the FDA's Orange Book
FTC's latest actions illustrate that Orange Book patent listings continue to be a priority for the agency. The Federal Trade Commission (FTC) ...
GSK, Novo and more resist FTC's latest patent crackdown
The eight pharma companies that face FTC's challenges against patents in the FDA's Orange Book ... Unrelenting antitrust scrutiny. The FTC ...
Warren Urges FTC To Closely Scrutinize Novo Nordisk-Catalent ...
... Orange Book, which would open opportunity for more competition and lower drug prices for Americans. In May 2024, Senator Warren and ...
The Antitrust Prescription - Edgeworth Economics
Product Hopping: Common Considerations · An Antitrust Economist's Perspective on Recent FTC Scrutiny towards Orange Book Patent Listing · Parsing NJ Court's ...
The Current Status of FTC'S Orange Book Listings Challenge
... FTC announced its intention to challenge more than one hundred Orange Book listings as improper. About six months later, on April 30, 2024 ...
FTC Alleges Improper Orange Book Listing of Drug Delivery Device ...
The Federal Trade Commission (FTC) announced on November 7, 2023, challenges to more than 100 patent listings by brand drug manufacturers in the Food and Drug ...
FTC Votes to Scrutinize High Drug Prices, Patent Listing Abuse
... Orange Book—an issue impacting consumers as pharmaceutical competitiveness and drug costs increase. The Democratic-led FTC said the ...
Will Trump Adopt the Current FTC's Antitrust Posture?
... higher drug prices, which changed the way federal enforcers saw these players. ... Orange Book Scrutiny. The FTC under Khan had also zeroed in on ...
The Antitrust Investigator Will See You Now: What Healthcare and ...
In another example of increased antitrust scrutiny, the Federal Trade Commission (FTC) ... Orange Book Policy: The FTC challenged more than ...
Orange Book Concerns Pick Up as Yet Another Issue for ...
... Orange Book patents that they assert are associated with their products. The Federal Trade Commission (FTC) issued a policy statement in ...
US FTC prepares for more scrutiny of Orange Book patents - BioWorld
The U.S. FTC put brand drug companies on notice Sept. 14 when the commissioners unanimously voted, 3-0, to issue a policy statement ...
FTC and DOJ Target Healthcare and Life Sciences Industries
should expect robust scrutiny by federal authorities and increased interagency ... Orange Book (Sept. 14,. 2023), https://www.ftc.gov/system ...
In Law360, Attorneys Examine FTC's Criticism of “Junk” Orange ...
In Law360, Attorneys Examine FTC's Criticism of “Junk” Orange Book Filings ... The authors note that during this time of heightened FTC scrutiny ...
Khan: FTC not finished with Orange Book patents
Chair Lina Khan has said that the Federal Trade Commission will challenge the legality of more drug patents listed for protection in the US Food and Drug ...
Three Drug Pricing Litigation Issues to Watch in the Second Half of ...
In September 2023, the Federal Trade Commission (FTC) issued a ... Orange Book To Allow for More Competition' (Jan. 18, 2024), https ...
Antitrust and Competition Life Sciences Quarterly Update Q2 2024
FTC Continues to Challenge Patent Listings in FDA Orange Book. While ... FTC More Time for Review,” April 8, 2024. Id. MLex ...
Orange Book alert: Improper patent listings could be investigated as ...
The FTC intends to scrutinize improper Orange Book listings to determine whether these constitute unfair methods of competition in violation of Section 5 of ...
Full Record | Library Website - MacEwan University
Increased Scrutiny by Federal Trade Commission of Orange Book Listings. ... Abstract. The Federal Trade Commission (FTC) has issued a policy statement ...